Add like
Add dislike
Add to saved papers

End-stage kidney disease in Fiji.

Internal Medicine Journal 2018 September 20
BACKGROUND: Chronic kidney disease is now a leading cause of death in Fiji. The country lacks even basic statistics about the incidence of end stage kidney disease (ESKD) and presents significant challenges to conducting clinical research.

AIM: To estimate the incidence and characteristics of ESKD in Fijian adults.

METHODS: A retrospective cohort study was conducted of patients admitted to Colonial War Memorial Hospital in Suva, Fiji in 2012. Suspected ESKD cases were identified from laboratory registers of renal function tests and confirmed through medical record review. Population data were from the Fijian Bureau of Statistics.

RESULTS: Screening identified 1474 suspected ESKD cases. Following removal of 763 duplicates and cases with discrepant identifiers, 711 unique cases remained. An additional 552 cases met exclusion criteria including acute kidney injury (247), failure to be admitted (131), and pre-existing ESKD diagnosis (103), leaving 159 cases of confirmed ESKD. Median age was 57 years (IQR 47-65). Crude and age-adjusted ESKD incidence rates were 753 per million population (pmp) (95% CI 636-870) and 793 pmp (95% CI 669-916) respectively, rising to 938 pmp (95% CI 804-1072) if African-American correction was removed. Diabetic nephropathy was the most common cause of ESKD (65·4%).

CONCLUSIONS: The incidence of ESKD in Fiji is high. This is a substantial public health problem that is likely impacting life expectancy and quality of life. Improving screening, detection and management of kidney disease should be given more prominence in programs to address non-communicable diseases in Fiji and the Western Pacific. This article is protected by copyright. All rights reserved.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app